Nasopharyngeal Cancer, is a type of head and neck cancer that affects the part of the throat connecting the back of the nose to the back of the mouth (nasopharynx). It should not be confused with other types of cancer that also affect the throat, such as laryngeal cancer and oesophageal cancer. Most of the nasopharyngeal cancers are nasopharyngeal carcinoma (NPC). There are mainly three types of NPC. They all start from epithelial cells that line the nasopharynx, but the cells of each type look different under a microscope. Three types include non-keratinizing undifferentiated carcinoma, non-keratinizing differentiated carcinoma, keratinizing squamous cell carcinoma.
DelveInsight's "Nasopharyngeal Cancer Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Nasopharyngeal Cancer market size and shares analysis in the seven major markets (7MM). The report also covers emerging drugs, current treatment practices, Nasopharyngeal Cancer Market Shares of the individual therapies, a detailed current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.
The report analyses the Nasopharyngeal Cancer Market trends and developments in the seven major markets (i.e. the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.
Nasopharyngeal Cancer Market Key Facts
- According to ASCO, Nasopharyngeal Cancer is uncommon in the United States, although it is more common in certain parts of North Africa, the Middle East, and Asia, particularly in southeast China. The risk of Nasopharyngeal Cancer increases slowly throughout life, but it can occur at any age, including in children.
- According to the study by Wang, Yu et al. titled “Racial differences in nasopharyngeal carcinoma in the United States” in age-specific cases the incidence rate was higher in patients more than 65 years of age, followed by patients of age between 40–64 years. The incidence rate was lower in patients of age less than 40 years. This study is the analysis of SEER data.
Nasopharyngeal Cancer Market Growth
The Nasopharyngeal Cancer market analysis section of the report helps to understand the current and forecasted Nasopharyngeal Cancer Market Trends and Growth by evaluating the impact of current therapies on the market, unmet needs, drivers, and barriers. The report gives complete detail of Nasopharyngeal Cancer Market Size and Shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Nasopharyngeal Cancer Epidemiology Insights
The epidemiology section covers detailed insights about the patient pool for every seven major countries. It helps to recognize the causes of current and forecasted Nasopharyngeal Cancer Epidemiology Trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Nasopharyngeal Cancer Epidemiology Segmentation
- Total Incidence of Nasopharyngeal Cancer in
- Gender-specific Incidence of Nasopharyngeal Cancer
- Age-specific Incidence of Nasopharyngeal Cancer
- Stage-wise Incidence cases of Nasopharyngeal Cancer
- Treated Pool of Nasopharyngeal Cancer
Nasopharyngeal Cancer Treatment Market
The mainstay of treatment for nasopharyngeal cancer is radiation therapy. In some cases surgery can be used, mainly to remove lymph nodes after chemo-radiotherapy or to treat nasopharyngeal cancer that has come back after initial treatment. There is a major unmet need for targeted or immunotherapies specifically targeting nasopharyngeal cancer. Also, the current treatment options are associated with several side effects which are hampering the patient’s quality of life as well as increasing the economic burden.
Currently, several companies are working towards the development of targeted therapies and immunotherapies for Nasopharyngeal Cancer because present treatments are associated with efficacy issues as well as side effects. The upcoming pipeline is robust for nasopharyngeal cancer, and several products are in the late stage of development which will immensely contribute to the growth of the upcoming therapeutic market of nasopharyngeal cancer.
Some of the key Nasopharyngeal Cancer Companies include BeiGene, Jiangsu HengRui, Harbour BioMed, Tessa Therapeutics, Innovent Biologics (Suzhou), Novartis Pharmaceuticals, and others. The Nasopharyngeal Cancer therapies covered in the report include TT10, Tislelizumab, Sintilimab, HBM9167, Donafenib, and many more.
For more details, visit: Nasopharyngeal Cancer Market Growth